About Contact Us Careers

Hemophilia A Treatment Market Size & Share, by Product (Plasma Derived Coagulation Factor Concentrate, Recombinant Coagulation Factor Concentrates, Antifibrinolytics, Desmopressin); Route of Administration (Intravenous, Oral, Nasal); Distribution Channel (Hospital Pharmacy, Retail Pharmacy and Online Pharmacy) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2025-2037

  • Report ID: 2422
  • Published Date: Jan 06, 2025
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2025-2037

Hemophilia A Treatment Market size is expected to expand at significant growth rate during the forecast period i.e., between 2025-2037.

Hemophilia is a condition in which the body is not able to form blood clots in order to stop bleeding. In a normal person’s body, the blood contains certain chemical substances which create a clot in case of bleeding. However, when a person has hemophilia, some clotting factors are absent which leads to the body being unable to form any clot. This result in continuous bleeding and eventually, severe loss of blood.

Hemophilia A is a rare genetic disorder of the blood characterized by a deficiency in the production of plasma protein factor VIII, which results in a reduced clotting property of the blood. Hemophilia drugs are given to hemophilic patients in order to provide them with these clotting factors artificially.

 

Growth Drivers

Rising Instances of Genetic Disorders to Boost the Market Growth

The cases of genetic disorders such as hemophilia have been growing significantly in the past few years and are estimated to grow further in the coming years. According to the National Hemophilia Foundation, Hemophilia A occurs in 1 out of 5,000 live male births in the United States. Additionally, hemophilia A is four times more common than hemophilia B. About 20,000 people in the United States are estimated to have hemophilia. Globally, around 400,000 people are predicted to be hemophilic. The report mentioned that approximately 75% of people with hemophilia do not receive proper treatment. On the back of these statistics, the market for hemophilia A drugs is anticipated to grow over the forecast period. 

Challenges

High Cost of Treatment for Hemophilia A to Restrict the Market Growth

The high costs associated with the drugs as well as the therapies available for hemophilia A treatment is predicted to make them unaffordable for a large section of the society, specially people belonging to the low- and middle-income countries. On the basis of this factor, the hemophilia A drugs market is estimated to observe limited growth in coming years.

Access Detailed Forecasts & Data-Driven Insights: Request Free Sample PDF

Hemophilia A Treatment Segmentation

The market is segmented by product, by route of administration, by distribution channel and by region, out of which, the product segment is further segmented into plasma derived coagulation factor concentrate, recombinant coagulation factor concentrates, antifibrinolytics, desmopressin and others. The segment for plasma derived coagulation factors is anticipated to hold the largest share in the hemophilia A treatment market on account of highest usage as compared with other products. Plasma derives coagulation factors further can be segmented into factors such as factor VIII, factor IX, factor XIII, von Willebrand factor and active prothrombin complex concentrates. As a result of this, the segment accounts for the highest share in the market. The segment for route of administration is further segmented into intravenous, oral, nasal and others, out of which, the intravenous segment currently holds the largest share in the market. Since the majority of hemophilia A treatment are in the form of injectable drugs, the market share of this route of administration is high. Moreover, administration of the drug directly into the blood is preferred over other routes. The segment for distribution channel is segmented into hospital pharmacy, retail pharmacy and online pharmacy. The segment for retail pharmacy is predicted to hold the leading share in the market as a result of growing preference of people for buying medicines are the pharmacies near their homes. On the other hand, the online pharmacy segment is anticipated to witness the highest growth rate on account of increasing demand of buying products online as ease of convenience of buying medications through online portals and having them delivered at home.

Our in-depth analysis of the global market includes the following segments:

By Product
  • Plasma Derived Coagulation Factor Concentrate
  • Recombinant Coagulation Factor Concentrates
  • Antifibrinolytics
  • Desmopressin 
  • Others

By Route of Administration
  • Intravenous
  • Oral
  • Nasal
  • Others

By Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
Vishnu Nair
Vishnu Nair
Head - Global Business Development

Customize this report to your requirements — connect with our consultant for personalized insights and options.

Hemophilia A Treatment Industry - Regional Synopsis

On the basis of regional analysis, the hemophilia A treatment market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. North America industry is poised to account for largest revenue share by 2037, attributed to recent advancements in the healthcare industry as well as the research and development of new drugs. Moreover, increased drug approvals further contribute towards the growth of market in this region. The market in Asia Pacific, however, is estimated to observe the highest growth rate over the forecast period as a result of rising number of patients with hemophilia A and growing awareness about the need for preventing and treating hemophilia in the region.

Hemophilia-A-Drugs-Market
Get Strategic Analysis by Region Now: Request Free Sample PDF

Companies Dominating the Hemophilia A Treatment Landscape

    • Pfizer Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Takeda Pharmaceutical Company Limited
    • F. Hoffmann-La Roche Ltd
    • Novo Nordisk A/S
    • Genzyme Corporation
    • Grifols, S.A.
    • CSL Behring
    • Octapharma AG
    • Aptevo Therapeutics
    • Ferring Pharmaceuticals

Recent Developments

  • On April 1, 2020, the U.S. Food and Drug Administration approved Sevenfact [coagulation factor VIIa (recombinant)-jncw], a drug containing a recombinant analog of human FVII as the active ingredient, for the treatment as well as control of bleeding in people above the age of 12 with hemophilia A or B.
  • Report ID: 2422
  • Published Date: Jan 06, 2025
  • Report Format: PDF, PPT
  • Get detailed insights on specific segments/region
  • Inquire about report customization for your industry
  • Learn about our special pricing for startups
  • Request a demo of the report’s key findings
  • Understand the report’s forecasting methodology
  • Inquire about post-purchase support and updates
  • Ask About Company-Level Intelligence Additions

Have specific data needs or budget constraints?

customer-service Inquiry Before Buying

Frequently Asked Questions (FAQ)

Hemophilia A Treatment Market size is expected to expand at significant growth rate during the forecast period i.e., between 2025-2037.

Hemophilia A Treatment Market size is expected to expand at significant growth rate during the forecast period i.e., between 2025-2037.

North America industry is poised to account for largest revenue share by 2037, attributed to recent advancements in the healthcare industry as well as the research and development of new drugs.

The major players in the market are Pfizer Inc., Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd, Novo Nordisk A/S, Genzyme Corporation, Grifols, S.A., CSL Behring, Octapharma AG, Aptevo Therapeutics and Ferring Pharmaceuticals.

Hemophilia A Drugs Market Report Scope

GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

Connect with our Expert

Radhika Pawar
Radhika Pawar
Senior Research Analyst
Get a Free Sample

See how top U.S. companies are managing market uncertainty — get your free sample with trends, challenges, macroeconomic factors, charts, forecasts, and more.

Inquiry Before Buying Request Free Sample PDF

Copyright @ 2025 Research Nester. All Rights Reserved.

footer-bottom-logos